# An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

> **NCT03900715** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 21 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT03900715
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-20
- **Primary completion:** 2022-07-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03900715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03900715, "An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03900715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*